GlassScriptPhysician profile
Monique Pouliot
NPI 1285674614
$3,654.18
in general payments reported to CMS, 2019-2025
29 companies · $790 in 2025
The $790 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2021: $23.22 · 2023: $935 · 2024: $1,623 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $461.96 | 2023-2025 | Farxiga, Fasenra, Breztri |
| Novo Nordisk INC | $446.29 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $430.43 | 2023-2025 | |
| Lilly USA, LLC | $364.37 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $237.76 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $190.13 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $133.90 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.62 | 2023-2024 | Jardiance, Tradjenta, Ofev |
| Astellas Pharma US INC | $102.74 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $83.01 | 2024-2025 | Gemtesa |
| Amgen INC. | $76.90 | 2019-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.24 | 2024-2025 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $50.57 | 2024 | Inspire |
| Shield Therapeutics INC | $45.72 | 2023 | Accrufer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $44.19 | 2019 | |
| Merck Sharp & Dohme LLC | $42.01 | 2023-2024 | Gardasil 9, M-M-R II, Varivax |
| Allergan, INC. | $38.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.81 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $32.19 | 2024 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $27.81 | 2025 | Neffy |
| Biogen, INC. | $26.61 | 2025 | Skyclarys |
| Amarin Pharma, INC. | $23.46 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.60 | 2023 | Voquezna |
| Corcept Therapeutics | $20.13 | 2024 | Korlym |
| Mylan Specialty L.P. | $18.94 | 2024 | Yupelri |
| Emergent Biosolutions INC. | $18.75 | 2019 | |
| Melinta Therapeutics, LLC | $15.25 | 2019 | |
| Radius Health, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Pouliot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.